Cardiology News / Recent Literature Review / Third Quarter 2018
Λέξεις-κλειδιά:
cardiology, news, literature reviewΠερίληψη
Rhythmos 2018;13(4):81-88.
HCS 39th Meeting: Athens, 18-20/10/2018
AHA Meeting: Chicago, IL, USA, 10-12/11/2018
ACC.19 Meeting: New Orleans, LA, USA, 16-18/3/2019
EHRA Congress: Lisbon, 17-19/3/2019
HRS Meeting: San Francisco, CA, USA, 8-11/5/2019
EuroPCR: Paris, 21-24/5/2019
ESC Meeting: Paris, 31/8-4/9/2019
NOACs are All Associated With a Significant Standardized Absolute Risk Reduction of MI Compared With VKA
Among 31,739 patients with atrial fibrillation (AF) (median age, 74 years; 47% females), the standardized 1-year risk of MI for VKA was 1.6%, 1.2% for apixaban, 1.2% for dabigatran, and 1.1% for rivaroxaban. No significant risk differences were observed in the standardized 1-year risks of MI among the NOACs: dabigatran vs apixaban (0.04%), rivaroxaban versus apixaban (0.1%), and rivaroxaban versus dabigatran (−0.1%). The risk differences for NOACs vs VKA were all significant: −0.4% for apixaban, −0.4% for dabigatran, and −0.5% for rivaroxaban (Lee CJ-Y et al, J Am Coll Cardiol 2018;72: 17–26).
ATLAS ACS 2-TIMI 51 Trial: In Patients With ACS, Addition of Rivaroxaban, 2.5 mg bid, to Dual Antiplatelet Therapy With Aspirin and Clopidogrel Was Associated With a Net Reduction in Fatal or Irreversible Events Compared to Dual Antiplatelet Therapy Alone
Rivaroxaban, 2.5 mg bid, in ACS patients treated with aspirin and clopidogrel/ticlopidine was associated with 115 fewer fatal or irreversible ischemic events (663 for placebo vs 548 for therapy) and 10 additional fatal or irreversible seriously harmful events (33 vs 23 for placebo) per 10,000 patient-years of exposure. Thus, there would be 105 fatal or irreversible events prevented per 10,000 patient-years of exposure to rivaroxaban compared with placebo, with 11 (10 of 115) fatal or irreversible ischemic events prevented for each fatal or irreversible seriously harmful event caused. If only nonbleeding cardiovascular death is included as a fatal or irreversible event, then 95 events would be prevented per 10,000 patient-years of exposure in the group taking 2.5 mg bid (Gibson CM et al, J Am Coll Cardiol 2018;72: 129-36)
XANTUS Program: In a Pooled Analysis of Several practice-Based Registries, AF Patients on Rivaroxaban Had Generally Low Rates of Stroke, Bleeding, and Treatment Discontinuation and Results Were Broadly Consistent Across Different Regions of the World
Among 11,121 AF patients receiving rivaroxaban (mean age 70.5±10.5 years; female 42.9%) with comorbidities including heart failure (21.2%), hypertension (76.2%), and diabetes (22.3%), event rates were: events/100 patient-years: major bleeding 1.7 (lowest: Latin America 0.7; highest: Western Europe, Canada, and Israel 2.3); all-cause death 1.9 (lowest: Eastern Europe 1.5; highest: Latin America, Middle East, and Africa 2.7); and stroke or systemic embolism 1.0 (lowest: Latin America 0; highest: East Asia 1.8). One-year treatment persistence was 77.4% (lowest: East Asia 66.4%; highest: Eastern Europe 84.4%) (Kirchhof P et al, J Am Coll Cardiol 2018;72:141-53)... (excerpt)
Λήψεις
Λήψεις
Δημοσιευμένα
Τεύχος
Ενότητα
Άδεια
Authors who publish with this journal agree to the following terms:
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
